Why This Matters for Your Career
Bristol Myers Squibb is hiring 10 roles related to this product
ATENOLOL (atenolol) by Bristol Myers Squibb is adrenergic beta-antagonists [moa]. Approved for hypertension, to lower blood pressure, the management of hemodynamically stable patients with definite and 4 more indications. First approved in 2019.
Adrenergic beta-Antagonists
beta-Adrenergic Blocker
Worked on ATENOLOL at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Randomized Controlled Study to Assess the Effects of Bisoprolol and Atenolol on Resting Heart Rate and Sympathetic Nervous System's Activity in Subjects With Essential Hypertension
Effect of Carvedilol Controlled-Release (CR) and Atenolol on Central Blood Pressure
Phase 1 Drug Interaction Study of Apixaban and Atenolol in Healthy Subjects
Safety and Efficacy of Valsartan vs Atenolol and Hydrochlorothiazide Combination on Blood Flow in Hypertensive Patients
Efficacy and Safety of Aliskiren and Atenolol in Adults (>18) With Mild to Moderate Hypertension
Bristol Myers Squibb is hiring 10 roles related to this product